FEN Clinical Trials

Brand Identity

Overview

About the project

Phase 3 clinical trial program to evaluate fenebrutinib in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). We were tasked with developing the brand identities for the studies and provide materials for HCP and patients in order to help enroll patients.

Date
August 2, 2021
My role
Art director, visual designer

Genentech/Roche was launching a Phase 3 clinical trial program to evaluate fenebrutinib, its investigational oral BTK inhibitor, in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). There were three clinical studies: one for FENhance (RMS) and one for FENtrepid (PPMS), and one for FENopta (RMS). Our agency was tasked with developing the brand identities for both studies as well as the overall brand identity for fenebrutinib, and provide materials for healthcare providers and patients in order to spread the word and enroll patients in these studies.

The process

I worked with our internal team and client contacts on several rounds of logo options, before settling on the final round.

No items found.
No items found.
Here is the main parent brand, Fenebrutinib, with the three sub-brand logos.
Here are some pieces from the FENtrepid collateral:
FENtrepid brand guidelines
FENtrepid collateral 1
FENtrepid collateral 2
FENtrepid website - home
No items found.
No items found.
And here are some selected pieces from the FENhance collateral:
FENhance brand guidelines
FENhance collateral 1
FENhance collateral 2
FENhance website - home
No items found.